Author

Li Yao

Cornell UniversityORCID 0000-0002-7785-5563Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Li Yao1 paper · The University of Texas Southwestern Medical Center

Biology Disciplines

Click to filter author papers

Genetics· 1 Genomics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:benchmarking· 1 Assay:ChIP-seq· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Abdullah OzeriD· 1 shared Alden King-Yung LeungiD· 1 shared Alejandro BarreraiD· 1 shared Anita GoleciD· 1 shared Aurélie HattoniD· 1 shared Avery Willis· 1 shared Batsheva KeremiD· 1 shared Chen LeibsoniD· 1 shared

Activity by Year

2021-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenomics

Abdullah OzerORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Comprehensive Evaluation of Diverse Massively Parallel Reporter Assays to Functionally Characterize Human Enhancers Genome-wide

Junke Zhang, Alden King-Yung Leung, Yutong Zhu, Li Yao, Avery Willis, Xiuqi Pan, Abdullah Ozer, Zhou Zhou, Keith Siklenka, Alejandro Barrera, Jin Hua Liang, Nathaniel D. Tippens, Timothy E. Reddy, John T. Lis, Haiyuan Yu

This study evaluates multiple MPRA and STARR-seq datasets to identify enhancers, finding inconsistencies due to technical factors and proposing a unified pipeline to improve cross-assay agreement.

Genome biology · Nov 3, 2025Peer-reviewedGenomics

Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10kb C-to-T splicing mutation

Yifat S. Oren, Michal Irony‐Tur Sinai, Anita Golec, Ofra Barchad-Avitzur, Venkateshwar Mutyam, Li Yao, Jeong Shin Hong, Efrat Ozeri-Galai, Aurélie Hatton, Chen Leibson, Liran Carmel, Joel M. Reiter, Eric J. Sorscher, Steve Donald Wilton, Eitan Kerem, , Batsheva Kerem

This study develops an antisense oligonucleotide (ASO) therapy for CF patients with the 3849+10kb C-to-T splicing mutation, showing restoration of CFTR function in patient-derived cells.

Journal of Cystic Fibrosis · Jul 2, 2021Peer-reviewedGenetics